1747030566313b92…

{
  "id": "NCT00087789",
  "type": "Study",
  "data": {
    "briefSummary": "This is a Phase I clinical study to assess the safety, tolerability and biologic activity of in vivo AAV-mediated delivery of CERE-110. Up to 12 subjects will receive open label CERE-110 in dose-escalating fashion. All subjects will receive bilateral, stereotactic injections of CERE-110 for a total of four (Dose A and B) and six (Dose C) injections to target the basal forebrain region of the brain containing the nucleus basalis of Meynert (NBM). All study participants will be observed for a 24-month period and then followed annually.",
    "completionDate": "2010-05",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "enrollmentCount": 10,
    "enrollmentType": "ACTUAL",
    "nctId": "NCT00087789",
    "phase": "PHASE1",
    "sponsorId": "sangamo-therapeutics",
    "startDate": "2004-06",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "A Phase I, Dose-Escalating Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-Based Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects With Mild to Moderate Alzheimer's Disease",
    "url": "https://clinicaltrials.gov/study/NCT00087789"
  }
}